Fasudil mesylate

甲磺酸法舒地尔

Report date: 2024/06/28 17:31:34

Base Information

Drug NameFasudil mesylate
Drug Alias Name朗来
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVoltage-gated calcium channel blockersRho-associated protein kinase 1 inhibitors
TargetsVoltage-gated calcium channelRho-associated protein kinase 1
Therapy Area/IndicationsAmyotrophic Lateral SclerosisVasospasm, IntracranialCerebral Infarction
Global Approved IndicationsVasospasm, IntracranialCerebral Infarction
Approved Indications in ChinaVasospasm, IntracranialCerebral Infarction
Original Approved Country/TerritoryMainland China
Original Approved Date2001/08/22
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesQr Pharma
China Registration ClassN/A

Develop Information

Active CompaniesAsahi Kasei Pharma America CorpWoolsey Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral SclerosisVasospasm, IntracranialCerebral Infarction
Inactive IndicationsN/A

Other Information

ATC CodeC04AX32
Related LinksN/A